Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | TMP | Common Stock | Options Exercise | $255K | +6.27K | +10.26% | $40.60 | 67.4K | Nov 15, 2022 | Direct | |
transaction | TMP | Common Stock | Tax liability | -$401K | -4.74K | -7.04% | $84.49 | 62.6K | Nov 15, 2022 | Direct | F1 |
transaction | TMP | Common Stock | Options Exercise | $371K | +7.53K | +12.02% | $49.22 | 70.2K | Nov 15, 2022 | Direct | |
transaction | TMP | Common Stock | Tax liability | -$512K | -6.06K | -8.63% | $84.49 | 64.1K | Nov 15, 2022 | Direct | F1 |
transaction | TMP | Common Stock | Options Exercise | $272K | +4.84K | +7.54% | $56.29 | 68.9K | Nov 15, 2022 | Direct | |
transaction | TMP | Common Stock | Tax liability | -$345K | -4.08K | -5.92% | $84.49 | 64.8K | Nov 15, 2022 | Direct | F2 |
holding | TMP | Common Stock | 9.96K | Nov 15, 2022 | by 401(k)/ISOP | ||||||
holding | TMP | Common Stock | 5.06K | Nov 15, 2022 | by ESOP |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | TMP | Stock Appreciation Rights (SAR) | Options Exercise | $0 | -6.27K | -100% | $0.00* | 0 | Nov 15, 2022 | Common Stock | 6.27K | $40.60 | Direct | F3 |
transaction | TMP | Stock Appreciation Rights (SAR) | Options Exercise | $0 | -7.53K | -100% | $0.00* | 0 | Nov 15, 2022 | Common Stock | 7.53K | $49.22 | Direct | F3 |
transaction | TMP | Stock Appreciation Rights (SAR) | Options Exercise | $0 | -4.84K | -100% | $0.00* | 0 | Nov 15, 2022 | Common Stock | 4.84K | $56.29 | Direct | F3 |
Id | Content |
---|---|
F1 | Shares withheld for option cost and taxes. |
F2 | Shares withheld for option cost and taxes. |
F3 | Stock Appreciation Rights (SARs) were granted pursuant to the Tompkins Financial Corporation 2009 Equity Plan. SARs have a seven year vesting schedule with 0% vesting in year one, 17% vesting in years two through six, and 15% vesting in year seven. When exercised, the SARs will be settled in Common Stock of the Company. The grant will expire ten years from the date of the grant. |